Abstract:Therapeutic antibodies must have "drug-like" properties. These include high affinity and specificity for the intended target, biological activity, and additional characteristics now known as "developability properties": long-term stability and resistance to aggregation when in solution, thermodynamic stability to prevent unfolding, high expression yields to facilitate manufacturing, low self-interaction, among others. Sequence-based liabilities may affect one or more of these characteristics. Improving the stability and developability of a lead antibody is typically achieved by modifying its sequence, a time-consuming process that often results in reduced affinity. Here we present a new antibody library format that yields high-affinity binders with drug-like developability properties directly from initial selections, reducing the need for further engineering or affinity maturation. The innovative semi-synthetic design involves grafting natural complementarity-determining regions (CDRs) from human antibodies into scaffolds based on well-behaved clinical antibodies. HCDR3s were amplified directly from B cells, while the remaining CDRs, from which all sequence liabilities had been purged, were replicated from a large next-generation sequencing dataset. By combining two in vitro display techniques, phage and yeast display, we were able to routinely recover a large number of unique, highly developable antibodies against clinically relevant targets with affinities in the subnanomolar to low nanomolar range. We anticipate that the designs and approaches presented here will accelerate the drug development process by reducing the failure rate of leads due to poor antibody affinities and developability.Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CQA: critical quality attribute; ELISA: enzyme-linked immunoassay; FACS: fluorescence-activated cell sorting; Fv: fragment variable; GM-CSF: granulocyte-macrophage colony-stimulating factor; HCDR3: heavy chain CDR3; IFN2a: interferon α-2; IL6: interleukin-6; MACS: magnetic-activated cell sorting; NGS: next generation sequencing; PCR: polymerase chain reaction; SEC: size-exclusion chromatography; SPR: surface plasmon resonance; TGFβ-R2: transforming growth factor β-R2; VH: variable heavy; VK: variable kappa; VL: variable light; Vl: variable lambda.

VCAb: A web-tool for structure-guided exploration of antibodies

VCAb: A web-tool for structure-guided antibody engineering

Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies

IsAb: a computational protocol for antibody design

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms

Five computational developability guidelines for therapeutic antibody profiling

AACDB: Antigen-Antibody Complex Database — a Comprehensive Database Unlocking Insights into Interaction Interface

Locuaz: an in-silico platform for antibody fragments optimization

Atomically accurate de novo design of single-domain antibodies

Finding Antibodies in Cryo-EM densities with CrAI

De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV‐2 spike receptor binding domain (RBD)

Antibodies: Computer-Aided Prediction of Structure and Design of Function

DLAB: deep learning methods for structure-based virtual screening of antibodies

AI-based IsAb2.0 for antibody design

On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality

An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF

A Novel Brick for Bispecific Antibody Construction

Learning the Language of Antibody Hypervariability